Will REDEFINE 3 delay approval?

It is not structured to. The application rests on the pivotal efficacy trials, and outcomes trials in this class routinely report after initial approval. Whether a regulator conditions anything on it is a matter for the regulator.

Why is it larger than the efficacy trials?

Because the endpoint is rare. Detecting a difference in event rates requires enough events to accumulate, and the only levers are the number of participants, the risk of the population enrolled and the duration of follow-up.

What is 'quadruple masked'?

A registry field describing how many parties are blinded - typically participant, care provider, investigator and outcomes assessor. It is a more precise statement than 'double-blind' and is what the registry records for this trial.

Does a weight reduction imply a cardiovascular benefit?

Not automatically, which is why these trials exist. Several interventions have reduced weight or improved a risk factor without reducing events, and the history of cardiovascular medicine contains enough such cases that regulators require the outcome to be measured directly.

Research & Regulatory News

7,101 Participants, and No Answer Until 2027

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-245 cited sources

REDEFINE 3 (NCT05669755) is a Phase 3 cardiovascular safety and efficacy trial of CagriSema, with 7,101 participants and a three-point MACE primary endpoint. Its primary completion date is 1 September 2027, so it will not inform the application currently before the FDA.

Key facts

Registration: NCT05669755
Registered acronym: REDEFINE 3
Design: Phase 3, quadruple-masked, placebo-controlled
Enrolment: 7,101 (actual)
Condition listed: Cardiovascular disease
Primary endpoint: Time to first three-point MACE
Started: 1 March 2023
Primary completion: 1 September 2027
Status: Active, not recruiting

Why a separate cardiovascular trial exists at all

Weight trials measure weight. Whether a drug that reduces weight also reduces cardiovascular events is a different question, requiring a different design: a much larger population selected for cardiovascular risk, followed for years rather than months, with events rather than measurements as the endpoint. REDEFINE 3 is that trial for CagriSema. It enrolled 7,101 participants - more than twice REDEFINE 1 - and its primary endpoint is the time to first occurrence of a three-point major adverse cardiovascular event, the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.

Why it takes so long

Because the endpoint is an event, and events accumulate slowly. A trial powered on a mean change in body weight can read out in 68 weeks because every participant contributes a measurement. A trial powered on MACE has to wait until enough participants have had an event for the comparison to be informative, which depends on the underlying event rate in the population enrolled and cannot be accelerated by measuring more often. REDEFINE 3 started on 1 March 2023 and has a primary completion date of 1 September 2027 - four and a half years, which is ordinary for this kind of trial.

What that timing means for the filing

The CagriSema application to the FDA rests on REDEFINE 1 and REDEFINE 2, both of which read out in 2024 and 2025. REDEFINE 3 will not contribute to it. That is not unusual: cardiovascular outcome trials in this class are typically required to be underway, and often to report after approval, rather than to precede it. Semaglutide's own cardiovascular indication came years after its initial approvals, on the basis of a separate outcomes trial. So a decision on CagriSema in 2026 would be a decision without cardiovascular outcome data, which is normal and is worth knowing when reading coverage that implies otherwise.

What a three-point MACE endpoint does and does not capture

It captures cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, and combines them into a single event count. Composites of this kind are used because each component alone would be too rare to power a trial on, and they carry a known interpretive cost: a result can be driven by one component while appearing as a benefit across all three. Any reported result should be read alongside the individual components, which trials of this kind report as secondary analyses precisely so that this can be checked.

Where it sits in the programme

REDEFINE 1 and 2 are the pivotal efficacy trials. REDEFINE 4 is the head-to-head against tirzepatide. REDEFINE 6 is a 300-participant trial in Chinese participants, of the kind run to support a regional submission where local data are expected. REDEFINE 3 is the outcomes trial and by far the largest, at 7,101 against 3,417, 1,206 and 300 respectively. A programme of that shape - a small number of large efficacy trials, one very large outcomes trial and several smaller regional or comparative studies - is what a serious obesity development plan now looks like.

Status and limits

Active, not recruiting, with primary completion in September 2027. Nothing about its result can be known or predicted, and this article makes no claim about what it will show. CagriSema is not licensed in any jurisdiction. Nothing supplied on this site is CagriSema, cagrilintide or semaglutide, and research material is never an alternative to a licensed medicine.

Quick reference

Trial	Registration	Enrolment	Primary completion	Role
REDEFINE 1	NCT05567796	3,417 randomised	30 October 2024	Pivotal, obesity
REDEFINE 2	NCT05394519	1,206 randomised	28 January 2025	Pivotal, type 2 diabetes
REDEFINE 3	NCT05669755	7,101	1 September 2027	Cardiovascular outcomes
REDEFINE 6	NCT05996848	300	6 January 2025	Chinese participants
REIMAGINE 2	NCT06065540	2,734	19 November 2025	Versus components

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Will REDEFINE 3 delay approval?: It is not structured to. The application rests on the pivotal efficacy trials, and outcomes trials in this class routinely report after initial approval. Whether a regulator conditions anything on it is a matter for the regulator.
Why is it larger than the efficacy trials?: Because the endpoint is rare. Detecting a difference in event rates requires enough events to accumulate, and the only levers are the number of participants, the risk of the population enrolled and the duration of follow-up.
What is 'quadruple masked'?: A registry field describing how many parties are blinded - typically participant, care provider, investigator and outcomes assessor. It is a more precise statement than 'double-blind' and is what the registry records for this trial.
Does a weight reduction imply a cardiovascular benefit?: Not automatically, which is why these trials exist. Several interventions have reduced weight or improved a risk factor without reducing events, and the history of cardiovascular medicine contains enough such cases that regulators require the outcome to be measured directly.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum